In this issue:
Recommendations for CV risk evaluation in psoriasis and PsA
Antibiotics and biologic discontinuation in psoriasis
Ixekizumab and malignant neoplasms
Childhood infections and psoriasis vulgaris in adulthood
Biologics and reduced risk of PsA
Systemic treatment of ICI-induced psoriasis
Treatment persistence after MACE in psoriasis
GPP clinical characteristics, treatment outcomes, and relapse
AI-based quantification to assess the automatic PASI
Social media intervention in psoriasis education and treatment adherence
Please login below to download this issue (PDF)